# Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

> **NCT02924311** · — · COMPLETED · sponsor: **Bayer** · enrollment: 402 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02924311
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-21
- **Primary completion:** 2019-08-12
- **Final completion:** 2019-12-06
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924311, "Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02924311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*